Skip to main navigation
Skip to search
Skip to main content
UT MD Anderson Cancer Center Home
Help & FAQ
Link opens in a new tab
Search content at UT MD Anderson Cancer Center
Home
Profiles
Research units
Equipment
Research output
Activities
Prizes
View Scopus Profile
Yu Shen
Professor
Biostatistics
https://orcid.org/0000-0002-3899-7868
h-index
13721
Citations
60
h-index
Calculated based on number of publications stored in Pure and citations from Scopus
1996 …
2026
Research activity per year
Overview
Fingerprint
Network
Research output
(255)
Similar Profiles
(12)
Fingerprint
Dive into the research topics where Yu Shen is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Medicine and Dentistry
Breast Cancer
100%
Malignant Neoplasm
48%
Overall Survival
44%
Neoplasm
36%
Diseases
31%
Radiation Therapy
20%
Neoadjuvant Chemotherapy
17%
Systemic Therapy
17%
Inflammatory Breast Cancer
17%
Estrogen Receptor
14%
Hormone Therapy
14%
Recurrent Disease
14%
Hormone Receptor
12%
Clinical Trial
12%
Metastatic Breast Cancer
11%
Cancer
11%
Breast Cancer Screening
10%
Proportional Hazards Model
10%
Mastectomy
10%
Acute Myeloid Leukemia
10%
Biopsy Technique
10%
Health Care Cost
9%
Mammography
9%
Contralateral
9%
Hazard Ratio
9%
Breast Surgery
9%
Myelodysplastic Syndrome
9%
Disease Free Survival
9%
Cost-Effectiveness Analysis
8%
Transitional Cell Carcinoma
8%
Comorbidity
8%
Triple Negative Breast Cancer
7%
Arm
7%
Quality of Life
7%
Patient-Reported Outcome
7%
Preventive Mastectomy
7%
Trastuzumab
7%
Surgeon
7%
Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
6%
Intraductal Carcinoma
6%
Breast Radiotherapy
6%
Biological Marker
6%
Cystectomy
6%
Prostate Cancer
6%
Survival Rate
6%
Quadrantectomy
5%
Medicare
5%
Cisplatin
5%
Prognostic Factor
5%
Receptor Expression
5%
Keyphrases
Overall Survival
30%
Inflammatory Breast Cancer
22%
Breast Cancer
19%
Neoadjuvant Chemotherapy
18%
HER2-positive
16%
Pathological Complete Response
16%
National Cancer Database
15%
Tumor
14%
Breast Cancer Patients
14%
Metastatic Breast Cancer
13%
Breast Reconstruction
13%
Chemotherapy
13%
Invasive Breast Cancer
12%
Neoadjuvant Systemic Therapy
10%
Confidence Interval
9%
Human Epidermal Growth Factor Receptor 2 (HER2)
8%
Length-biased Data
8%
Endocrine Therapy
7%
Ductal Carcinoma in Situ
7%
Breast
7%
Clinical Outcomes
7%
Accelerated Partial Breast Irradiation
7%
Triple-negative Breast Cancer
7%
Hormone Receptor-positive
6%
Estrogen Receptor-positive
6%
Breast Cancer Screening
6%
MD Anderson Cancer Center
6%
Trastuzumab
6%
Disease-free Survival
6%
Cohort Data
6%
Early Breast Cancer
6%
Acute Myeloid Leukemia
5%
Complete Response Rate
5%
Adjuvant Endocrine Therapy
5%
Disease-specific Survival
5%
Cancer Center
5%
Locoregional Recurrence
5%
Consensus Guidelines
5%
Cox Model
5%
Phase II Trial
5%
Hazard Ratio
5%
Exceptional Responders
5%
Anthracyclines
5%